Efecto en el sangrado perioperatorio durante la resección transuretral de la próstata tras un mes de tratamiento con dutasteride

Arratia-Maqueo, J.A.; Garza-Cortés, R.; Gómez‐Guerra, Lauro Salvador; Cortés-González, J.R.

doi:10.1016/j.acuro.2010.06.005

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hahn et al showed no significant reductions in postoperative bleeding among patients taking 5-alpha-reductase for 2 weeks before transurethral resection of the prostate [21]. In a similar study, Arratia-Maqueo et al also showed no significant reductions in postoperative bleeding among patients taking the same medicine for a longer time period of 4 weeks [22]. …”

Section: Discussionmentioning

confidence: 99%

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

Zamuner

Falcone

Neto

et al. 2014

Advances in Urology

View full text Add to dashboard Cite

Background. Benign prostatic hyperplasia (BPH) pharmacological treatment may promote a decrease in prostate vascularization and bladder neck relaxation with theoretical improvement in prostate biopsy morbidity, though never explored in the literature. Methods. Among 242 consecutive unselected patients who underwent prostate biopsy, after excluding those with history of prostate biopsy/surgery or using medications not for BPH, we studied 190 patients. On the 15th day after procedure patients were questioned about symptoms lasting over a week and classified according to pharmacological BPH treatment. Results. Thirty-three patients (17%) were using alpha-blocker exclusively, five (3%) 5-alpha-reductase inhibitor exclusively, twelve (6%) patients used both medications, and 140 (74%) patients used none. There was no difference in regard to age among groups (P = 0.5). Postbiopsy adverse effects occurred as follows: hematuria 96 (50%), hematospermia 53 (28%), hematochezia 22 (12%), urethrorrhagia 19 (10%), fever 5 (3%), and pain 20 (10%). There was a significant negative correlation between postbiopsy hematuria and BPH pharmacological treatment with stronger correlation for combined use of 5-alpha-reductase inhibitor and alpha-blocker over 6 months (P = 0.0027). Conclusion. BPH pharmacological treatment, mainly combined for at least 6 months seems to protect against prostate biopsy adverse effects. Future studies are necessary to confirm our novel results.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

Zamuner

Falcone

Neto

et al. 2014

Advances in Urology

View full text Add to dashboard Cite

show abstract

“…In two recent studies, one RCT and an other an observational prospective study, aimed at exploring the role dutasteride versus placebo on reducing blood loss during and after TURP procedures, found no significance in dutasteride's use to reduce blood loss [17, 18]. Hahn et al reported that dutasteride reduced 86–89% of the serum DHT level after 2 weeks of treatment [18].…”

Section: Discussionmentioning

confidence: 99%

“…Despite this, there was no significant difference in blood loss between the groups either during or after TURP ( P > 0.05), in addition to no difference in the MVD between the dutasteride group and the control group ( P > 0.05) [18]. In a study by Arratia-Maqueo et al using dutasteride and placebo, they report no difference in blood loss after TURP ( P = 0.88), Hb decrease ( P = 0.73), or resected prostatic chipping weight ( P = 0.87) [17]. However, they do mention that 33% of the patients on dutasteride had significant symptom improvement and did not require TURP [17].…”

Section: Discussionmentioning

confidence: 99%

“…In a study by Arratia-Maqueo et al using dutasteride and placebo, they report no difference in blood loss after TURP ( P = 0.88), Hb decrease ( P = 0.73), or resected prostatic chipping weight ( P = 0.87) [17]. However, they do mention that 33% of the patients on dutasteride had significant symptom improvement and did not require TURP [17]. This might explain why no difference was found when compared to the placebo group as the patients who improved could have altered the results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Should Finasteride Be Routinely Given Preoperatively for TURP?

et al. 2013

View full text Add to dashboard Cite

Objective. The aim of the review was to compare the use of finasteride to placebo in patients undergoing TURP procedures. Material & Methods. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966–November 2011), EMBASE (1980–November 2011), CINAHL, Clinicaltrials.gov, Google Scholar, reference lists of articles, and abstracts from conference proceedings without language restriction for studies comparing finasteride to placebo patients needing TURPs. Results. Four randomised controlled trials were included comparing finasteride to a placebo. A meta-analysis was not conducted due to the disparity present in the results between the studies. Three of the studies found that finasteride could reduce either intra- or postoperative bleeding after TURP. One study found finasteride to significantly lower the microvessel density (MVD) and vascular endothelial growth factor (VEGF). None of the studies reported any long-term complications related to either the medication or the procedure. Conclusion. finasteride reduces bleeding either during or after TURP.

show abstract

WITHDRAWN: Transurethral Resection of Prostate and Bleeding: A Prospective Randomized, Double-blind, Placebo-controlled Trial to See Efficacy of Short-term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density

Arora

Bansal

Purkait

et al. 2016

Urology

View full text Add to dashboard Cite

show abstract

Efecto en el sangrado perioperatorio durante la resección transuretral de la próstata tras un mes de tratamiento con dutasteride

Abstract: Dutasteride did not significantly impact the studied variables in these non randomized and small sample size settings.

Cited by 6 publications

References 21 publications

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

Should Finasteride Be Routinely Given Preoperatively for TURP?

WITHDRAWN: Transurethral Resection of Prostate and Bleeding: A Prospective Randomized, Double-blind, Placebo-controlled Trial to See Efficacy of Short-term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density

Contact Info

Product

Resources

About